Professor Paresh Vyas

Paresh Vyas is Professor of Haematology at the University of Oxford. He is a research-active Consultant Haematologist at the Oxford University Hospitals NHS Trust with a clinical practice in myeloid disorders which include AML and, myelodysplastic syndrome.

He is leading key opinion leader in AML. He is on the UK AML clinical trial group and co-founder of the international EVOLVE consortium that delivers novel trials in AML and high risk MDS. He founded and directs the Therapy Acceleration Laboratory at the University of Oxford that provides central laboratory analyses for Phase I-III trials. He also runs a basic and translational laboratory in the Weatherall Institute where he focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He is Deputy Director at the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine. He has been a co-author of several important scientific publications covering AML.

Paresh studied medicine at the University of Cambridge and then the University of Oxford. He did his medical and haematology training at hospitals in London. He obtained his Ph.D. with Professor Doug Higgs at the MRC Molecular Haematology Unit, Oxford and then conducted a three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University.